日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Bone targeting nanocarrier-assisted delivery of adenosine to combat osteoporotic bone loss

骨靶向纳米载体辅助输送腺苷以对抗骨质疏松性骨质流失

期刊:Biomaterials
影响因子:12.8
doi:10.1016/j.biomaterials.2021.120819
Jiaul Hoque, Yu-Ru V Shih, Yuze Zeng, Hunter Newman, Nivedita Sangaj, Neha Arjunji, Shyni Varghese
代谢
骨质疏松
发表日期：2021
文献求助 收藏

Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1

生存率、运动功能和运动里程碑：AVXS-101 与 Nusinersen 治疗 1 型脊髓性肌萎缩症患儿的比较

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-019-00923-8
Dabbous, Omar; Maru, Benit; Jansen, Jeroen P; Lorenzi, Maria; Cloutier, Martin; Guérin, Annie; Pivneva, Irina; Wu, Eric Q; Arjunji, Ramesh; Feltner, Douglas; Sproule, Douglas M
神经科学
肌萎缩症
发表日期：2019
文献求助 收藏

Response to: Alfred Sandrock, Wildon Farwell. Letter to the Editor, Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, et al. Adv Ther (2019) 36(5):1164-76. doi:10.1007/s12325-019-00923-8

回复：Alfred Sandrock、Wildon Farwell。《致编辑的信：独立开展的临床试验的比较：关于Dabbous O、Maru B、Jansen JP、Lorenzi M、Cloutier M、Guérin A等人的信》。Adv Ther (2019) 36(5):1164-76。doi:10.1007/s12325-019-00923-8

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-019-01088-0
Dabbous, Omar; Maru, Benit; Jansen, Jeroen P; Lorenzi, Maria; Cloutier, Martin; Guérin, Annie; Pivneva, Irina; Wu, Eric Q; Arjunji, Ramesh; Feltner, Douglas; Sproule, Douglas M
发表日期：2019
文献求助 收藏